A survey suggests drug firms need to better inform consumers about nonsteroidal anti-inflammatory drugs' potential risks and could tap into a sales growth driver in a sizeable group of consumers who are ignoring their pain.
The research by consultancy Kelton Global for pharmaceutical NSAID marketer Iroko Pharmaceuticals LLC found that 61% of US consumers...